138 related articles for article (PubMed ID: 18006781)
1. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781
[TBL] [Abstract][Full Text] [Related]
2. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
4. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
6. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
7. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
8. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
Liu W; Innocenti F; Wu MH; Desai AA; Dolan ME; Cook EH; Ratain MJ
Cancer Res; 2005 Jan; 65(1):46-53. PubMed ID: 15665278
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK; von Bubnoff N; Peschel C; Duyster J
Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor mutations in small cell lung cancer.
Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor structural alterations in gastric cancer.
Moutinho C; Mateus AR; Milanezi F; Carneiro F; Seruca R; Suriano G
BMC Cancer; 2008 Jan; 8():10. PubMed ID: 18199332
[TBL] [Abstract][Full Text] [Related]
12. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.
Yung TK; Chan KC; Mok TS; Tong J; To KF; Lo YM
Clin Cancer Res; 2009 Mar; 15(6):2076-84. PubMed ID: 19276259
[TBL] [Abstract][Full Text] [Related]
13. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Amador ML; Oppenheimer D; Perea S; Maitra A; Cusatis G; Iacobuzio-Donahue C; Baker SD; Ashfaq R; Takimoto C; Forastiere A; Hidalgo M
Cancer Res; 2004 Dec; 64(24):9139-43. PubMed ID: 15604284
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study.
Mustea A; Sehouli J; Fabjani G; Koensgen D; Möbus V; Braicu EI; Pirvulescu C; Thomas A; Tong D; Zeillinger R
Anticancer Res; 2007; 27(3B):1527-30. PubMed ID: 17595771
[TBL] [Abstract][Full Text] [Related]
15. Impact of EGFR mutation analysis in non-small cell lung cancer.
Yamamoto H; Toyooka S; Mitsudomi T
Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
[TBL] [Abstract][Full Text] [Related]
16. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.
Sasaki H; Kawano O; Endo K; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2007 Feb; 17(2):319-23. PubMed ID: 17203167
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
19. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
20. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]